CY1117170T1 - Συνθεση ολιγοσακχαριτων για προληψη ή μειωση του κινδυνου μεταβολικου συνδρομου - Google Patents

Συνθεση ολιγοσακχαριτων για προληψη ή μειωση του κινδυνου μεταβολικου συνδρομου

Info

Publication number
CY1117170T1
CY1117170T1 CY20161100102T CY161100102T CY1117170T1 CY 1117170 T1 CY1117170 T1 CY 1117170T1 CY 20161100102 T CY20161100102 T CY 20161100102T CY 161100102 T CY161100102 T CY 161100102T CY 1117170 T1 CY1117170 T1 CY 1117170T1
Authority
CY
Cyprus
Prior art keywords
risk
prevent
reduce
metabolic syndrome
composition
Prior art date
Application number
CY20161100102T
Other languages
English (en)
Inventor
Georgios Tzortzis
Jelena Vulevic
Original Assignee
Clasado Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clasado Inc. filed Critical Clasado Inc.
Publication of CY1117170T1 publication Critical patent/CY1117170T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Η παρούσα εφεύρεση αφορά τη χρήση σύνθεσης γαλακτοολιγοσακχαριτών για την πρόληψη ή μείωση του κινδύνου ανάπτυξης μεταβολικού συνδρόμου.
CY20161100102T 2011-07-05 2016-02-08 Συνθεση ολιγοσακχαριτων για προληψη ή μειωση του κινδυνου μεταβολικου συνδρομου CY1117170T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1111452.7A GB2492559B (en) 2011-07-05 2011-07-05 Composition and method for preventing or reducing the risk of developing a syndrome
EP12731143.9A EP2729152B1 (en) 2011-07-05 2012-06-20 Oligosaccharides composition for preventing or reducing the risk of metabolic syndrome

Publications (1)

Publication Number Publication Date
CY1117170T1 true CY1117170T1 (el) 2017-04-05

Family

ID=44512110

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20161100102T CY1117170T1 (el) 2011-07-05 2016-02-08 Συνθεση ολιγοσακχαριτων για προληψη ή μειωση του κινδυνου μεταβολικου συνδρομου

Country Status (24)

Country Link
US (2) US11052097B2 (el)
EP (1) EP2729152B1 (el)
JP (1) JP2014518253A (el)
KR (1) KR20140041597A (el)
CN (2) CN103648504A (el)
AR (1) AR087062A1 (el)
AU (1) AU2012203730B2 (el)
BR (1) BR112013030308A2 (el)
CA (1) CA2838309C (el)
CY (1) CY1117170T1 (el)
DK (1) DK2729152T3 (el)
ES (1) ES2562993T3 (el)
GB (1) GB2492559B (el)
HU (1) HUE027148T2 (el)
IL (1) IL230251A (el)
MX (1) MX337612B (el)
MY (1) MY173722A (el)
PL (1) PL2729152T3 (el)
PT (1) PT2729152E (el)
RU (1) RU2571079C2 (el)
TW (1) TWI461200B (el)
UA (1) UA111616C2 (el)
WO (1) WO2013005001A1 (el)
ZA (1) ZA201308776B (el)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2492559B (en) * 2011-07-05 2018-07-25 Clasado Inc Composition and method for preventing or reducing the risk of developing a syndrome
GB201319538D0 (en) 2013-11-05 2013-12-18 Optibiotix Health Ltd Composition
KR102029263B1 (ko) * 2018-05-16 2019-11-08 주식회사 비피도 베타-엘-푸코피라노실-(1→3)-옥시-디-갈락토피라노오스를 포함하는 프리바이오틱스 조성물
GB2623336A (en) * 2022-10-12 2024-04-17 Clasado Res Services Limited Compositions and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62210965A (ja) * 1986-03-13 1987-09-17 Shokuhin Sangyo Baioriakutaa Syst Gijutsu Kenkyu Kumiai 低カロリ−飲食品およびその製造方法
JP2699470B2 (ja) * 1988-10-19 1998-01-19 大日本インキ化学工業株式会社 食品保存剤及びその製造方法
US6368591B2 (en) * 1998-05-15 2002-04-09 Shanghai Sine Pharmaceutical Corporation Ltd. Beneficial microbe composition, new protective materials for the microbes, method to prepare the same and uses thereof
ITMI20002019A1 (it) * 1999-09-17 2002-03-15 Novartis Ag Metodo per il trattemento dei disturbi metabolici, in particolare diabete oppure una malattia oppure una condizione associate con il diabete
JP2003339348A (ja) * 2002-05-27 2003-12-02 Toyo Shinyaku:Kk 健康食品
GB0315266D0 (en) * 2003-06-30 2003-08-06 Clasado Inc Novel galactooligosaccharide composition and the preparation thereof
PT1644482E (pt) * 2003-06-30 2007-06-25 Clasado Inc Nova composição de galacto-oligossacáridos e sua preparação.
DE102005034262A1 (de) * 2005-07-22 2007-01-25 Bayer Healthcare Ag Substituierte Pyridocarboxamide II
WO2008054193A1 (en) * 2006-11-02 2008-05-08 N.V. Nutricia Nutritional products that comprise saccharide oligomers
EP2143341A1 (en) 2008-07-08 2010-01-13 Nestec S.A. Nutritional Composition Containing Oligosaccharide Mixture
GB0809921D0 (en) * 2008-05-30 2008-07-09 Clasado Inc Product and process therefor
JP5238373B2 (ja) * 2008-06-25 2013-07-17 株式会社ヤクルト本社 腸間膜脂肪低減剤
GB0906983D0 (en) * 2009-04-23 2009-06-03 Clasado Inc Novel use
UA104469C2 (uk) * 2009-05-27 2014-02-10 Класадо Інк. Спосіб запобігання діареї мандрівників
US8951512B2 (en) * 2010-05-04 2015-02-10 New York University Methods for treating bone disorders by characterizing and restoring mammalian bacterial microbiota
GB2492559B (en) * 2011-07-05 2018-07-25 Clasado Inc Composition and method for preventing or reducing the risk of developing a syndrome
GB201305708D0 (en) * 2013-03-28 2013-05-15 Clasado Inc Novel use

Also Published As

Publication number Publication date
TW201313235A (zh) 2013-04-01
HUE027148T2 (en) 2016-10-28
RU2014103800A (ru) 2015-08-10
MX2013015036A (es) 2014-02-17
CN107744522A (zh) 2018-03-02
MX337612B (es) 2016-03-10
GB2492559A (en) 2013-01-09
RU2571079C2 (ru) 2015-12-20
NZ617764A (en) 2015-08-28
ES2562993T3 (es) 2016-03-09
WO2013005001A1 (en) 2013-01-10
BR112013030308A2 (pt) 2016-11-29
CN103648504A (zh) 2014-03-19
EP2729152B1 (en) 2015-12-30
GB201111452D0 (en) 2011-08-17
PT2729152E (pt) 2016-03-04
ZA201308776B (en) 2015-04-29
US11052097B2 (en) 2021-07-06
JP2014518253A (ja) 2014-07-28
KR20140041597A (ko) 2014-04-04
UA111616C2 (uk) 2016-05-25
US20140142061A1 (en) 2014-05-22
US20210330688A1 (en) 2021-10-28
DK2729152T3 (en) 2016-01-25
AU2012203730B2 (en) 2013-10-31
TWI461200B (zh) 2014-11-21
GB2492559B (en) 2018-07-25
EP2729152A1 (en) 2014-05-14
MY173722A (en) 2020-02-18
AU2012203730A1 (en) 2013-01-24
CA2838309C (en) 2017-04-18
IL230251A (en) 2017-03-30
AR087062A1 (es) 2014-02-12
PL2729152T3 (pl) 2016-06-30
CA2838309A1 (en) 2013-01-10

Similar Documents

Publication Publication Date Title
CY1124924T1 (el) Φαρμακευτικη συνθεση καρβετοκινης
CR20150507A (es) Inhibidores de histona desmetilasas
UY34472A (es) Derivados modificados de 4-fenil-piridina
TR201811764T4 (tr) Kinaz inhibitörleri olarak aminoheteroaril benzamidleri.
CR20150120A (es) Nuevos derivados bicíclicos
CR20140501A (es) Nuevos diazaespirocicloalcanos y azaespirocicloalcanos
UY34550A (es) Bencilpirazoles sustituidos
UY34145A (es) Compuestos inhibidores de metaloenzimas
UY34146A (es) Compuestos inhibidores de metaloenzimas
CR20140468A (es) Inhibidores de diacilglicerol aciltransferasa 2
UY34414A (es) Composiciones hemostáticas
CR20140229A (es) Nuevos derivados bicíclicos de dihidroisoquinolin-1-ona
UY34177A (es) Nuevos compuestos inhibidores de la fosfodiesterasa tipo 10a
CR20130539A (es) Triazolopiridinas
EA201390081A1 (ru) Дейтерированный n-этил-n-фенил-1,2-дигидро-4-гидрокси-5-хлор-1-метил-2-оксохинолин-3-карбоксамид, его соли и их применение
CL2012002979A1 (es) Derivados de n3-sustituido-n1-sulfonil-5-fluorpirimidinona.
UY34654A (es) Inhibidores de la beta-secretasa
UY34817A (es) Tienopirimidinas
UY34057A (es) Inhibidores del virus de la hepatitis c
BR112013025866A2 (pt) formulações com viscosidade reduzida
UY34415A (es) Composiciones hemostáticas
CY1120759T1 (el) Παρασκευη διγλυκοζιτη (s,s)-σεκοϊσολαρικιρεσινολης και διγλυκοζιτη (r,r)-σεκοϊσολαρικιρεσινολης
BR112014003027A2 (pt) formulação herbicida melhorada
DK3021839T3 (da) Sammensætninger for behandling af fibrose
UY34158A (es) Composicion herbicida